Clinical Study Synopsis
|
|
- Liliana Lambert
- 5 years ago
- Views:
Transcription
1 Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labeling information approved for the patient's country or region. Data in this document or on the related website should not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug. The following information is the property of Bayer HealthCare AG. Reproduction of all or part of this report is strictly prohibited without prior written permission from Bayer HealthCare AG. Commercial use of the information is only possible with the written permission of the proprietor and is subject to a license fee. Please note that the General Conditions of Use and the Privacy Statement of bayerhealthcare.com apply to the contents of this file.
2 Clinical Trial Results Synopsis Study Design Description Study Sponsor: Bayer Healthcare AG Study Number: 504 NCT Study Phase: N/A Official Study Title: Activity and tolerability of BAY B % vaginal cream in patients with vaginal Candida infections (open, mycologically controlled study). Therapeutic Area: Anti-Infectives Test Product Name of Test Product: Canesten (Clotrimazole, BAY B 5097) 10% vaginal cream Name of Active Ingredient: Dose and Mode of Administration: bis-phenyl-(2-chlorophenyl)-1-imidazolyl-methane (Clotrimazole) Single intravaginal dose of about 5.0 g of cream (500 mg of the active substance), administed by the doctor with the aid of an applicator. Reference Therapy/Placebo Reference Therapy: Not applicable Dose and Mode of Administration: Not applicable Duration of Treatment: Duration of treatment was one day. Studied period: Date of first subjects first visit: January 1982 Date of last subjects last visit: May 1982 Study Center(s): The study was conducted at single center in Germany Page 1 of 4
3 Methodology: The material for the detection of pathogens by culture was collected by a vaginal smear. Detection of pathogens by culture constituted the main criterion for including the subject in the study. If a positive native preparation was not confirmed by mycological culture, the subject was excluded from the rest of the study and evaluated only in respect to local tolerability. Before the start of treatment, the severity of the infection was classified into one of three grades on the basis of the clinical symptoms: "Slight": colposcopy revealed no visible alteration of the vaginal mucosa "Moderate": colposcopy revealed visible alteration of the vaginal mucosa "Severe": macroscopically visible alteration of the vaginal mucosa. The therapeutic results were checked on the basis of mycological (native preparation and culture) and clinical findings, one and four weeks after the end of therapy. The final evaluation of the clinical outcome was based on the following criteria: normalization (cure) was assumed when objectively discernible, individual symptoms were no longer present and the subject was not suffering from any subjective complaints. In the case of subjects with clinical symptoms and positive mycological findings at the first check-up, the doctor conducting the therapy was free to initiate a substitute therapy. Such cases were classified as "failures" and were included in the evaluation as such. At the first follow-up, the subjects were asked to state the day after the treatment on which the subjective complaints were eliminated. At the first check-up, the subjects were asked about the acceptability and local tolerability of the cream. Any local intolerance was recorded. Indication/ Test Indication: Main Inclusion Criteria: Vaginal yeast infection. Inclusion criteria: Clinical findings of a vaginal yeast infection. Mycological findings: o Positive native preparation with detection of pseudomycelia o Confirmation by the detection of pathogens in the culture. Study Objectives: Overall: To investigate the therapeutic activity and tolerability of BAY B % vaginal cream in subjects with vaginal yeast infections, within the framework of an open, mycologically controlled study. Primary: To demonstrate therapeutic activity and local tolerability of the test product. Page 2 of 4
4 Evaluation Criteria: Efficacy (Primary): One and four weeks after the end of the therapy, the therapeutic results were checked on the basis of mycological (native preparation and culture) and clinical findings of a vaginal yeast infection. Safety: Tolerance by the subjects to the study drug application Statistical Methods: Efficacy (Primary): The results of the mycological and clinical tests were presented in the form of multi-field tables. The evaluation was carried out with routines of the BMDP program package (univariate description) and the SAS program package. Safety: Data regarding tolerability of the drug was collected. Number of Subjects: The study was planned to include 30 subjects. Forty subjects were enrolled and 34 were evaluated. Five subjects were not evaluated as they did not meet inclusion criteria, and one subject did not attend follow-up examinations. Study Results Results Summary Subject Disposition and Baseline The 34 subjects included in the evaluation were between 16 and 52 years old (median age 26 years), weighed 49 to 104 kg (median weight 60 kg), and were 159 to 172 cm tall (median height 167 cm). In 18 subjects, the anamnestic investigation revealed a primary infection and in 16 subjects, a recurrent vaginal yeast infection. On the basis of the clinical picture there were four subjects with of a "slight" form of infection, 18 subjects with a "moderate" form of infection and 12 subjects with a "severe" form of infection. In the majority of the subjects, the infection had been present for up to one week. Candida albicans was identified as the causative organism in 26 subjects (76%), Torulopsis glabrata in 5 subjects (15%), and Candida krusei in one subject. In two subjects, it was not possible to identify the Candida species. Results Summary Efficacy At the first follow-up examination with data on 32 subjects, the culture findings were negative in 24 subjects (75%). At the time of the second follow-up, culture findings were negative in 21 of the 27 subjects (78%). The native preparation results indicated 31 of 34 subjects (91%) gave negative native smear findings at the first follow-up exam. Three of these were positive at the second exam. Of the three subjects with positive native findings at the first exam, one was negative at the second exam, one remained positive, and there was no exam for the third. Page 3 of 4
5 The clinical symptoms in the majority of subjects were eliminated by the treatment. Twelve subjects (36%) reported improvement on the first day, 13 subjects (39%) on the second day, seven subjects (21%) on the third day and one subject on the fourth day after treatment. There was no information regarding this evaluation for one subject. Twenty-nine subjects complained of itching before the treatment. This symptom was eliminated in 26 (90%) of the subjects. Twenty-three subjects reported burning before the start of the treatment. Twenty-one of these (91%) no longer reported burning at the first check-up. Thrush patches were detected in 20 subjects before the start of the therapy. These were eliminated in all 20 subjects at the time of the first check-up. At the first follow-up exam, the concomitant vulvitis that had been diagnosed in 25 subjects before the therapy was eliminated. Before the start of the treatment 32 subjects exhibited a pathological alteration of the vaginal skin. At the first check-up, the redness observed in 24 subjects had been eliminated. Thirty-one out of 34 subjects (91%) were "successfully treated" at the first check-up; three of them relapsed at the second check-up. Of the three subjects assessed as treated without success at the first follow-up exam, two were later evaluated as successfully treated; in the third subject, no investigation was performed. In all, five subjects did not undergo a second check-up. Of the total of 29 subjects for whom a clinical evaluation of the treatment was made at the second follow-up exam, 26 were "successfully treated" Results Summary Safety Side effects were recorded in three of the 34 subjects. There were two cases of "burning" and one for which no specific details were available. No side effects were recorded in the five subjects who were eliminated from the overall evaluation. Conclusion(s) On the basis of the results of this study, BAY B % vaginal cream single dose therapy was effective in treating vaginal yeast infections. In this study, the subjects tolerated BAY B % vaginal cream. Publication(s): Not applicable Date Created or Date Last Updated: 18 Aug 2011 Page 4 of 4
Clinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationWebposting Clinical Trial Results Synopsis
Study Summary This summary information is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This summary information is not intended to replace
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationWe customize individual prescriptions for the specific needs of our patients.
We customize individual prescriptions for the specific needs of our patients. J A N U A R Y 2 0 1 3 I N S I D E T H I S I S S U E : Vulvodynia 2 Vulvovaginal Candidiasis Breastfeeding Challenges 3 4 P
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Report
Clinical Study Report No. H 552 000-0902 / 290102BS page 1 of 40 Clinical Study Report Sponsor: Study No.: H 552 000-0902 / 290102BS EudraCT-No.: 2009-009948-23 Title: Study Preparation: A phase IIa single-center,
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationCANDIDIASIS (WOMEN) Single Episode. Clinical Features. Diagnosis. Management
CANDIDIASIS (WOMEN) What s new: Section on Management of Vulvovaginal Non-Albicans Candida Infection in Adults approved by GGC antimicrobial team Routine candida sensitivity testing has been discontinued,
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationComparison of Boric Acid with Clotrimazole in the Treatment of Recurrent or Resistant Vulvovaginitis Caused by Non-Albicans Species of Candida
IJMS Vol 33, No 4, December 2008 Original Article Comparison of Boric Acid with Clotrimazole in the Treatment of Recurrent or Resistant Vulvovaginitis Caused by Non-Albicans Species of Candida N. Khadem,
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationLocation of study report in Regulatory Dossier for authorities
This document has been downloaded from www.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationGynofort (butoconazole nitrate) Vaginal Cream, 2.0%
Gynofort (butoconazole nitrate) Vaginal Cream, 2.0% Rx Only Decription Butoconazole Nitrate Vaginal Cream, 2.0% contains butoconazole nitrate 2%, an imidazole derivative with antifungal activity. Its chemical
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Synopsis for Public Disclosure
Clinical Study Synopsis for Public Disclosure These results are supplied for informational purposes only in the interest of scientific disclosure. The synopsis may include approved and non-approved uses,
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClincialTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClincialTrials.gov
More informationLatest Press Release. Cloud9games.tk
corp@stantec.com Latest Press Release Cloud9games.tk S (Dorland, 27th ed); Infection with a fungus of the genus candida; usually a superficial infection of the moist areas of the body and is generally
More informationPage: Pre-test screening for eligible subjects was performed during the 28 days before the anticipated study start (Day 1).
This document has been downloaded from www.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationLocation of study report in Regulatory Dossier for authorities
This document has been downloaded from www.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationCommunity Gynaecology. Top Tips for GPs
Community Gynaecology Top Tips for GPs Top Tips for GPs Case Scenarios- common referral themes 6 topics What you can do in Primary Care to avoid or before referral. What we don t need to see Triage ensures
More informationPrincipal Investigator: Robert J. Jones, MD, Beatson Cancer Center, 1053 Great Western Road, Glasgow; United Kingdom
SYNOPSIS Issue Date: 14 October 2010 Document No.: EDMS-ERI-13494974:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Protocol No.: COU-AA-BE Cougar Biotechnology, Inc.
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationComplex Vaginitis Cases: Applying New Diagnostic Methods to Enhance Patient Outcomes ReachMD Page 1 of 5
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationSponsor / Company: Sanofi Drug substance(s): artesunate plus amodiaquine Title of the study:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationPARTICIPANT DIARY TREATMENT ALLOCATION: LACTIC ACID GEL
PARTICIPANT DIARY TREATMENT ALLOCATION: LACTIC ACID GEL For site staff completion only: Participating Site: Participant Initials: Participant ID: Date of Randomisation: Allocated Treatment: Lactic Acid
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationIf you are searching for the book Refractory Candida vulvovaginitis on the rise.(infectious DISEASES)(Report): An article from: Family Practice News
Refractory Candida Vulvovaginitis On The Rise.(INFECTIOUS DISEASES)(Report): An Article From: Family Practice News [HTML] [Digital] By Patrice Wendling READ ONLINE If you are searching for the book Refractory
More informationHuman Immunodeficiency Virus-Positive Women
Infectious Diseases in Obstetrics and Gynecology 8:176-180 (2000) (C) 2000 Wiley-Liss, Inc. Determinants of Incident Vulvovaginal Candidiasis in Human Immunodeficiency Virus-Positive Women Emma Shifrin,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationClinical Policy: Carbidopa-Levodopa ER Capsules (Rytary) Reference Number: CP.CPA.148 Effective Date: Last Review Date: 08.
Clinical Policy: (Rytary) Reference Number: CP.CPA.148 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationCanesten Clotrimazole Thrush Treatment Once Cream
Canesten Clotrimazole Thrush Treatment Once Cream Clotrimazole vaginal cream 100 mg/g What is in this leaflet This leaflet answers some common questions about Canesten Thrush Treatment. It does not contain
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationth Street Urbandale, IA YOST
YfC 3993 100th Street Urbandale, IA 50322 515.278.YOST www.yostfamilychiropractic.com Demographics: Language (Primary) Race: Unspecified American Indian or Alaska Native Black or African American Other
More informationPrevalence and Management of Non-albicans Vaginal Candidiasis
Prevalence and Management of Non-albicans Vaginal Candidiasis Nalin Hetticarachchi, Ruth Ashbee, Janet D Wilson To cite this version: Nalin Hetticarachchi, Ruth Ashbee, Janet D Wilson. Prevalence and Management
More informationDiflucan dosage for yeast infection on the breast
Diflucan dosage for yeast infection on the breast The Borg System is 100 % Diflucan dosage for yeast infection on the breast Mar 2, 2015. Fluconazole (Diflucan) is a synthetic antifungal agent which can
More informationMeda Pharmaceuticals
MP03-33 Nasal Spray Page 1 of 9 Meda Pharmaceuticals Active-Controlled Trial of the Safety and Tolerability of MP03-33 in Patients with Chronic Allergic or Nonallergic Rhinitis (MP432) FINAL CLINICAL STUDY
More informationCanesten Clotrimazole Thrush 3 Day Cream
Canesten Clotrimazole Thrush 3 Day Cream Clotrimazole internal vaginal cream 20 mg/g What is in this leaflet This leaflet answers some common questions about Canesten Clotrimazole Thrush 3 Day Cream. It
More informationClinical Trial Report Synopsis. Patient insights following use of LEO aerosol foam and Daivobet gel in subjects with psoriasis vulgaris
This document has been downloaded from W\vw.leo-pharma.com subject to the ten:n.s of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
1 SYNOPSIS (CR002878) Title of Study: The effect of on vasomotor symptoms in healthy postmenopausal women: a double-blind placebo controlled pilot study Investigators: Multiple, see Section 4, Investigators
More information